Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
Which drugs does patent 8,062,652 protect, and when does it expire?
| Title: | Compositions and methods for treating precocious puberty |
| Abstract: | The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP). |
| Inventor(s): | Kuzma; Petr (Princeton, NJ) |
| Assignee: | Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA) |
| Application Number: | 11/155,822 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Device; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharm | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | RX | Yes | Yes | ► Subscribe | ► Subscribe | METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY | ||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 1773293 | ► Subscribe | |||||||||||||
| Canada | 2570960 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2006009801 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,764 others who get our Drug Patent Expiration Alerts:
